BridgeBio Pharma racks up $299.2 mln

BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, has raised $299.2 million in funding. KKR and Viking Global Investors led the round with participation from other investors that included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, Hercules Capital and Sequoia Capital.